Targeted Therapy

The most efficacious targeted therapies for VEXAS syndrome are Janus kinase inhibitors and interleukin-6 inhibitors, while IL-1 and TNF blockers are less effective, according to data published in the Annals of the Rheumatic Diseases.

Sikander Ailawadhi, MD, discusses positioning different therapies and navigate the treatment landscape in multiple myeloma.

Healio spoke with Akriti Jain, MD, about the pre-MDS conditions that have the potential to progress into MDS if left untreated.

In this video, Eunice Wang, MD, discusses data presented at the ASH Annual Meeting and Exposition that validates menin inhibitors as a new class of targeted therapy for AML.

Black men with metastatic castration-resistant prostate cancer appear less likely to receive targeted therapies than white men, according to data published in JAMA Network Open.

Healio spoke with Sara M. Tolaney, MD, MPH, about the difficulties of treating de novo metastatic breast cancer.

Healio spoke with David Andrew Sallman, MD, about unmet needs in myelodysplastic syndrome.

An analysis of nearly 500 million cholesterol readings globally shows LDL levels vary widely by country and region even after adjusting for age and sex, suggesting population-specific interventions may be needed, researchers reported.

Healio spoke with Karen L. Reckamp, MD, about research on perioperative lung cancer presented at ASCO Annual Meeting.

DESTIN, Fla. — Although new targets and therapies are on the horizon, current myositis treatment strategies rely on treating impacted organ groups, according to a speaker at the 2023 Congress of Clinical Rheumatology-East.